Leukotriene receptor inhibitors primarily function by blocking which type of receptor?

Leukotriene receptor inhibitors primarily function by blocking Gq receptors. These receptors are part of a signaling pathway that mediates the effects of leukotrienes, which are inflammatory mediators involved in conditions such as asthma and allergic responses. By inhibiting these receptors, the drugs prevent leukotrienes from exerting their effects on bronchoconstriction and mucus production, ultimately helping to alleviate symptoms associated with respiratory conditions.

Leukotriene receptors, particularly the cysteinyl leukotriene receptor (CysLT1), are coupled to Gq proteins, which activate phospholipase C. This leads to a series of downstream effects that promote inflammation, bronchoconstriction, and other responses that are undesirable in conditions like asthma. Therefore, blocking Gq receptors helps reduce these inflammatory processes and improve airway function.

Understanding the role of Gq receptors in the action of leukotriene receptor inhibitors is critical when considering their therapeutic application in managing asthma and other allergic conditions.